Ranbaxy Laboratories Ltd has informed BSE that ICRA has assigned the rating of ?[ICRA]A1+? (pronounced as A One Plus) to the Company?s Commercial Paper (CP)/Short Term Debt (STD) programme for an enhanced amount of Rs. 800 Crores. Earlier CP/STD programme of the Company for Rs.1200 Crores was also assigned the same rating i.e. ?[ICRA]A1+?.
Instruments with ?[ICRA]A1+? rating are considered to have very strong degree of safety regarding timely payment of financial obligations. Such instruments carry lowest credit risk.
वैल्यू रिसर्च से पूछें 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
